Efficacy of indomethacin compared with magnesium sulfate in the management of preterm labor in pregnancies less than 32 weeks

Authors

  • Jehad Ayoub
  • Lina Ramadan
  • Ayman Nasra

Abstract

The study was made  on a sample of 100 pregnancies with preterm labour whom admitted to Tishreen University Hospital, Lattakia, Department of Obstetrics and Gynecology, during the period of May 2016 until May 2017
- Indomethacin and magnesium sulphate activities  were studied for inhibition of preterm labor, the most important side effects during treatment and physical  costfor  using indomethacin and comparing it with the physical cost for  using magnesium sulfate.
- The success rate of indomethacin for  inhibition of labour during the first 48 hours of treatment (86%) while success rate of magnesium therapy (78%) was the same as the previous period.

- The average period of time from the start of treatment until the disappearance of uterine contractions was lower in women treated with indomethacin than in women treated with magnesium sulfate and this difference is important in terms of statistical.

- The lowest period of inhibition of labor was 8.4. Days for women who were treated with indomethacin versus 3.8 days for women treated with magnesium sulfate by a statistically significant difference.

- The most significant side effects caused by the application of indomethacin and the most frequent is (nausea) by (54%) of the total side effects.
- The most important side effects caused by the application of Magnesium sulfate and the most frequent is (flushing ) by (66%) of the total side effects
- Indomethacin application by rectal  in preterm  labour inhibition was found to be less costly than using magnesium sulphate.

مقارنة فعالية الإندوميتاسين وسلفات المغنزيوم في تدبير
المخاض الباكر للحوامل بعمر حملي أقل من 32 أسبوع

أجريت الدراسة على عينة مكونة من 100 حالة من المريضات الحوامل المقبولات بقصة مخاض باكر في قسم التوليد وامراض النساء في مشفى تشرين الجامعي – اللاذقية خلال الفترة الممتدة من أيار 2016 حتى أيار 2017

-   تم دراسة فعالية كل من الإندوميتاسين وسلفات المغنزيوم في تثبيط المخاض الباكر ودراسة أهم التأثيرات الجانبية خلال المعالجة ودراسة التكلفة المادية لاستعمال الإندوميتاسين ومقارنتها مع التكلفة المادية لاستعمال سلفات المغنزيوم

-   بلغت نسبة نجاح الإندوميتاسين في تثبيط المخاض بطريقة (الجرعة) لمدة 48 ساعة الاولى من المعالجة

-   (  86% ) بينما كانت نسبة نجاح المعالجة بسلفات المغنزيوم (  78% ) لنفس المدة السابقة

-   أن متوسط الفترة الزمنية منذ بدء العلاج حتى زوال التقلصات الرحمية كانت أقل عند السيدات المعالجات بالاندوميتاسين منه عند السيدات المعالجات بسلفات المغنيزيوم وكان هذا الفرق هاما من الناحية الاحصائية .

-   بلغ متوسط أقل  فترة تم فيها تثبيط  المخاض 8.4 يوماعند السيدات المعالجات بالاندوميتاسين مقابل 3.8 يوماعند السيدات المعالجات بسلفات المغنيزيوم بفارق احصائي هام .

-   أهم الآثار الجانبية الناجمة عن تطبيق الإندوميتاسين وأكثرها تواردا (الغثيان) بنسبة (54%) من مجمل الأثار الجانبية .

-   أهم الآثار الجانبية الناجمة عن تطبيق سلفات المغنزيوم وأكثرها تواردا ( التوهج) بنسبة ( 66% ) من مجمل الأثار الجانبية

كما تبين أن تطبيق الإندوميتاسين عن طريق الشرج في تثبيط المخاض الباكر هو أقل تكلفة مادية من استعمال سلفات المغنزيوم.

Downloads

Published

2018-09-27

How to Cite

1.
Ayoub J, Ramadan L, Nasra A. Efficacy of indomethacin compared with magnesium sulfate in the management of preterm labor in pregnancies less than 32 weeks. Tuj-hlth [Internet]. 2018Sep.27 [cited 2024Nov.24];39(4). Available from: https://journal.tishreen.edu.sy/index.php/hlthscnc/article/view/3986

Issue

Vol. 39 No. 4 (2017): العلوم الصحية

Section

Articles

License

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

The authors retain the copyright and grant the right to publish in the magazine for the first time with the transfer of the commercial right to Tishreen University Journal for Research and Scientific Studies - Health Sciences Series

 Under a CC BY- NC-SA 04 license that allows others to share the work with of the work's authorship and initial publication in this journal. Authors can use a copy of their articles in their scientific activity, and on their scientific websites, provided that the place of publication is indicted in  Tishreen University Journal for Research and Scientific Studies - Health Sciences Series   .  The Readers have the right to send, print and subscribe to the initial version of the article, and the title of  Tishreen University Journal for Research and Scientific Studies - Health Sciences Series  Publisher

journal uses a CC BY-NC-SA license which mean

You are free to:

  • Adapt — remix, transform, and build upon the material
  •  
  • The licensor cannot revoke these freedoms as long as you follow the license terms.

 

  • Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
  • NonCommercial — You may not use the material for commercial purposes.
  • ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
  • No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

Most read articles by the same author(s)